Rocket


Overview
Financials
News + Filings
Key Docs
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Monopar Therapeutics (MNPR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: " "
08/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: " "
07/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: " ",
" "
06/28/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/01/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update"
05/11/2023 8-K Quarterly results
Docs: "Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments"
03/27/2023 8-K Quarterly results
03/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments"
02/27/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials"
02/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin"
01/26/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Therapeutics Inc."
01/18/2023 8-K Quarterly results
12/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Therapeutics Inc."
11/16/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/05/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/20/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Capital on DemandTM Sales Agreement, by and between Monopar Therapeutics Inc. and JonesTrading Institutional Services LLC",
"Opinion of Baker & Hostetler LLP"
04/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/24/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments"
02/15/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Announces Clinical and Preclinical Program Updates"
12/08/2021 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments"
10/27/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "ADDITIONAL EXHIBITS"
09/16/2021 8-K Quarterly results
09/13/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
08/03/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma WILMETTE, Ill., August 3, 2021 – Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced clearance from the US Food and Drug Administration to proceed under its IND with an open-label Phase 1b dose-escalation trial evaluating camsirubicin plus growth factor support in patients with advanced soft tissue sarcoma . The Company anticipates dosing the first patient in the trial in the fourth quarter of this year. “By giving concomitant growth factor support to overcome the dose-limiting toxicity of this cla..."
07/12/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monopar Therapeutics Inc."
07/02/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/24/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy